These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
91 related articles for article (PubMed ID: 6598493)
41. Metabolism of budralazine, a new antihypertensive agent. I. Identification of the metabolites of budralazine in rats. Moroi R; Ono K; Saito T; Sano M; Akimoto T Chem Pharm Bull (Tokyo); 1976 Nov; 24(11):2850-6. PubMed ID: 1017113 [No Abstract] [Full Text] [Related]
43. Arylphthalazines. Part 2: 1-(Isoquinolin-5-yl)-4-arylamino phthalazines as potent inhibitors of VEGF receptors I and II. Duncton MA; Piatnitski EL; Katoch-Rouse R; Smith LM; Kiselyov AS; Milligan DL; Balagtas C; Wong WC; Kawakami J; Doody JF Bioorg Med Chem Lett; 2006 Mar; 16(6):1579-81. PubMed ID: 16386418 [TBL] [Abstract][Full Text] [Related]
44. Metabolism of budralazine, a new antihypertensive agent. II. Metabolic pathways of budralazine in rats. Moroi R; Ono K; Saito T; Akimoto T; Sano M Chem Pharm Bull (Tokyo); 1977 Apr; 25(4):830-5. PubMed ID: 880722 [No Abstract] [Full Text] [Related]
45. Synthesis and anticonvulsant activity of 6-alkoxy-[1,2,4]triazolo[3,4-a]phthalazines. Zhang L; Guan LP; Sun XY; Wei CX; Chai KY; Quan ZS Chem Biol Drug Des; 2009 Mar; 73(3):313-9. PubMed ID: 19207467 [TBL] [Abstract][Full Text] [Related]
46. [Unexpected anti-inflammatory activity of rigid structures derived from antihypertensive 6-arylpyridazinones. III. Synthesis and activity of 7-fluoro- and 5-keto-5H-indeno(1,2-c)pyridozines]. Cignarella G; Loriga M; Pinna GA; Pirisi MA; Schiatti P; Selva D Farmaco Sci; 1982 Feb; 37(2):133-44. PubMed ID: 7067808 [TBL] [Abstract][Full Text] [Related]
49. The E.L.S.A. trial: protocol of a randomized trial to explore the differential effect of antihypertensive drugs on atherosclerosis in hypertension. Bond G; Dal Palú C; Hansson L; Magnani B; Mancia G; Neiss A; Rahn KH; Reid JL; Rodicio JL; Safar M J Cardiovasc Pharmacol; 1994; 23 Suppl 5():S85-7. PubMed ID: 7609514 [No Abstract] [Full Text] [Related]
50. Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy. Wexler RR; Greenlee WJ; Irvin JD; Goldberg MR; Prendergast K; Smith RD; Timmermans PB J Med Chem; 1996 Feb; 39(3):625-56. PubMed ID: 8576904 [No Abstract] [Full Text] [Related]
51. 1-(Azolyl)-4-(aryl)-phthalazines: novel potent inhibitors of VEGF receptors I and II. Kiselyov AS; Semenova M; Semenov VV; Piatnitski EL Chem Biol Drug Des; 2006 Nov; 68(5):250-5. PubMed ID: 17177884 [TBL] [Abstract][Full Text] [Related]
52. Studies on ecarazine hydrochloride (apiracohl). II. Spectrofluorometric determination of ecarazine hydrochloride and its metabolite in plasma. Ishii A; Deguchi T Chem Pharm Bull (Tokyo); 1978 Jul; 26(7):2241-6. PubMed ID: 688536 [No Abstract] [Full Text] [Related]
53. Synthesis of new 2-[1(2H)-phthalazinon-2-yl]acetamide and 3-[1(2H)-phthalazinon-2-yl]propanamide derivatives as antinociceptive and anti-inflammatory agents. Dogruer DS; Kupeli E; Yesilada E; Sahin MF Arch Pharm (Weinheim); 2004 Jun; 337(6):303-10. PubMed ID: 15188219 [TBL] [Abstract][Full Text] [Related]
55. Synthesis and structure-activity relationships of 1-aminophthalazinium bromides as GABAA receptor ligands. Catarzi D; Cecchi L; Filacchioni G; Bartolini A; Carpenedo R; Galli A; Mori F Drug Des Discov; 1993; 10(1):23-34. PubMed ID: 8399992 [TBL] [Abstract][Full Text] [Related]
56. Synthesis of new derivatives of 4-hydroxy-(2H)-phthalazinone and phthalazino-1,4-(2H)(3H)-dione. Otto-Jaworska T Acta Pol Pharm; 1992; 49(4):81-3. PubMed ID: 16092441 [TBL] [Abstract][Full Text] [Related]
57. Compliance studies in ELSA. European Lacidipine Study of Atherosclerosis. Giannattasio C; Boutouyrie P; Glen S; Mallion J; Reid J; Laurent S; Mancia G Blood Press Suppl; 1996; 4():39-43. PubMed ID: 8973782 [No Abstract] [Full Text] [Related]
58. Synthesis and antihypertensive activity of some 3-substituted 4H-1,2,4-triazoles. Emilsson H; Selander H Acta Pharm Suec; 1983; 20(6):419-32. PubMed ID: 6675421 [No Abstract] [Full Text] [Related]